The BEACON study used de-identified data from the Tempus Database, assessing IB6 expression via immunohistochemistry.

Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...

Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...

mRNA vaccines can enhance immunotherapy efficacy by activating the immune system, improving outcomes in hard-to-treat tumors. mRNA COVID-19 vaccines enhance immune responses, improving cancer ...

Menopause care is not one-size-fits-all, especially for gender nonconforming individuals, including transgender, nonbinary ...

Newly analyzed data from Japan adds to the evidence that COVID-19 may increase the risk of shingles.

Veterans who enter the healthcare workforce have a 29% higher chance at promotion and have a 14% higher retention rate than ...

Managed Healthcare Executive interviewed OneHome’s Noel Gilliam, Vice President of Value-Based Product Design, to discuss the ...

Serum DR-70 levels are higher in bladder cancer patients, especially in muscle-invasive cases, indicating potential for diagnosis and staging. Current diagnostic methods for bladder cancer are ...

Expert discusses how the prevalence of chronic kidney disease (CKD), as reflected by decreased estimated glomerular ...

Milliman’s Jennifer Cruz says plans are losing rebates because of steep price discounts negotiated under the Inflation ...

More than half of melanoma patients whose cancer initially responds to immunotherapy will eventually see their disease return ...